| Catalog No. | Size | Price (USD) |
| 105342-T40-50 | 50 µL | $147.96 |
| 105342-T40-100 | 100 µL | $251.64 |
| 105342-T40-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-HLA-DR Antibody, Rabbit Polyclonal |
| Validated applications | WB (FAQ Protocol), IHC-P (FAQ Protocol) |
| Species reactivity | Reacts with: Human, Cynomolgus |
| Specificity | Human, Cynomolgus |
| Immunogen | A synthetic peptide corresponding to the center region of the Human HLA-DR |
| Preparation | Produced in rabbits immunized with a synthetic peptide corresponding to the center region of the Human HLA-DR, and purified by antigen affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A & Antigen Affinity |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Image / Experimental Information
| Image 1 Description | Anti-HLA-DR rabbit polyclonal antibody at 1:500 dilution Lane A: Raji Whole Cell Lysate Lane B: Daudi Whole Cell Lysate Lane C: HuT-78 Whole Cell Lysate Lysates/proteins at 30 μg per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size:29 kDa Observed band size:33 kDa |
| Image 1 Alt Text | Human HLA-DR Western blot (WB) 19303 |
| Image 1 URL | Source image |
| Image 2 Description | Anti-HLA-DR rabbit polyclonal antibody at 1:500 dilution Lane A: Raji Whole Cell Lysate Lane B: Daudi Whole Cell Lysate Lane C: HuT-78 Whole Cell Lysate Lysates/proteins at 30 μg per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size:29 kDa Observed band size:33 kDa |
| Image 2 Alt Text | Human HLA-DR Immunohistochemistry(IHC) 19304 |
| Image 2 URL | Source image |
| Image 3 Description | Anti-HLA-DR rabbit polyclonal antibody at 1:500 dilution Lane A: Raji Whole Cell Lysate Lane B: Daudi Whole Cell Lysate Lane C: HuT-78 Whole Cell Lysate Lysates/proteins at 30 μg per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size:29 kDa Observed band size:33 kDa |
| Image 3 Alt Text | Human HLA-DR Immunohistochemistry(IHC) 19305 |
| Image 3 URL | Source image |
| Image 4 Description | Anti-HLA-DR rabbit polyclonal antibody at 1:500 dilution Lane A: Raji Whole Cell Lysate Lane B: Daudi Whole Cell Lysate Lane C: HuT-78 Whole Cell Lysate Lysates/proteins at 30 μg per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size:29 kDa Observed band size:33 kDa |
| Image 4 Alt Text | Human HLA-DRA Immunohistochemistry(IHC) 21225 |
| Image 4 URL | Source image |
| Image 5 Description | Anti-HLA-DR rabbit polyclonal antibody at 1:500 dilution Lane A: Raji Whole Cell Lysate Lane B: Daudi Whole Cell Lysate Lane C: HuT-78 Whole Cell Lysate Lysates/proteins at 30 μg per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size:29 kDa Observed band size:33 kDa |
| Image 5 Alt Text | Human HLA-DRA Immunohistochemistry(IHC) 21246 |
| Image 5 URL | Source image |
Background Information
| Description | HLA-DR is a major histocompatibility complex (MHC) class II antigen presentation molecule, critical for the activation of lymphocytes and the orchestration of adaptive immune responses. HLA-DR is normally expressed on antigen-presenting cells including monocytes, macrophages, dendritic cells and B cells, but expression can be induced on epithelial cells and tumour cells in response to inflammatory conditions. MHC class II antigen presentation molecules are responsible for presentation of exogenous antigens to CD4 helper T cells. HLA-DR expression in tumours has been positively associated with enhanced lymphocytic infiltration. HLA-DR has been used as a surrogate marker of immune competence in various clinical studies, and its loss in circulation has been linked with susceptibility to post-surgical infection and sepsis. |
| References |
|
title: MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy
authors: Ravindra Pramod Deshpande; Kerui Wu; ...; Kounosuke Watabe
journal: EMBO Molecular Medicine
date: 2025-03-14
pmid: 40087501
doi: 10.1038/s44321-025-00213-7
pmcid: 11982318
cited_by_count: 3
techniques: AST Assay; Activation Assay; Bradford Protein Assay; Cell Isolation; Enzyme-linked Immunosorbent Assay; Expressing; Fluorescence; Incubation; Isolation; Over Expression; Plasmid Preparation; Proliferation Assay; Recombinant; Red Blood Cell Lysis; Sequencing; Software; Staining; Western Blot; cDNA Synthesis
bioz_score: 93
-HD11NO1077-WB.png){kind=link}
-HD11NO1077-10000-human-liver-IHC-P.png){kind=link}
-HD11NO1077-10000-human-skin-IHC-P.png){kind=link}
-HD11NO1077-10000-cynomolgus-liver-IHC-P.png){kind=link}
-HD11NO1077-10000-cynomolgus-skin-IHC-P.png){kind=link}